Neumora Therapeutics (NMRA) Accounts Payables (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Accounts Payables of $5.1 million for Q1 2026, up 380.7% year-over-year from $1.1 million in Q1 2025, and up 49.66% quarter-over-quarter from $3.4 million in Q4 2025.
Neumora Therapeutics (NMRA) Accounts Payables (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Accounts Payables history runs 5 years deep, the most recent figure standing at $5.1 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 380.7% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $5.1 million (up 380.7% YoY), while the FY2025 annual figure was $3.4 million, up 2.18% from the prior year.
- Accounts Payables for Q1 2026 stood at $5.1 million, up from $3.4 million in the prior quarter.
- The five-year high for Accounts Payables was $7.1 million in Q4 2022, with the low at $337000.0 in Q4 2023.
- The 5-year median for Accounts Payables is $1.9 million (2023), against an average of $2.7 million.
- The sharpest annual moves came in 2023 and 2024: Accounts Payables slumped 95.28% in 2023, then surged 881.31% in 2024.
- Neumora Therapeutics' Accounts Payables stood at $7.1 million in 2022, then plunged by 95.28% to $337000.0 in 2023, then soared by 881.31% to $3.3 million in 2024, then advanced by 2.18% to $3.4 million in 2025, then jumped by 49.66% to $5.1 million in 2026.
- Business Quant data shows NMRA's Accounts Payables at $5.1 million in Q1 2026, $3.4 million in Q4 2025, and $549000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | 5.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.06 Mn |
| Dec 31, 2025 | 3.38 Mn |
| Sep 30, 2025 | 549,000.00 |
| Jun 30, 2025 | 644,000.00 |
| Mar 31, 2025 | 1.05 Mn |
| Dec 31, 2024 | 3.31 Mn |
| Sep 30, 2024 | 6.11 Mn |
| Jun 30, 2024 | 1.08 Mn |
| Mar 31, 2024 | 1.49 Mn |
| Dec 31, 2023 | 337,000.00 |
| Sep 30, 2023 | 2.23 Mn |
| Dec 31, 2022 | 7.15 Mn |